MedTech Terms
    The authoritative reference
    All terms
    ManufacturingManufacturing & Supply

    Endotoxin Testing (LAL)

    Detection of bacterial endotoxin on devices, typically using Limulus Amebocyte Lysate (LAL) assays.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Endotoxin contamination from gram-negative bacteria can cause severe pyrogenic reactions even after sterilization. LAL methods (gel-clot, turbidimetric, chromogenic) are standardized in USP <85> and ISO 10993-1 references. Devices contacting blood, the cardiovascular system or cerebrospinal fluid have limits, commonly 20 EU per device, or 2.15 EU per device for intrathecal contact, as described in FDA guidance and ANSI/AAMI ST72. Recombinant Factor C tests are a newer alternative to LAL that avoids horseshoe crab blood. Testing usually occurs on lot samples before release.
    What the regulation says
    USP <85>, Bacterial Endotoxins Test, outlines the official methodology for endotoxin testing, specifying acceptable limits and test procedures. Similarly, the FDA expects manufacturers to control endotoxin levels in medical devices, particularly those with direct or indirect patient contact, as described in their guidance documents on medical device biocompatibility. ISO 10993-1, Biological evaluation of medical devices, also references the need for endotoxin control as part of a device's overall biological safety assessment, though it does not specify test methods.

    What this means in practice

    Required for blood-contacting and implantable devices; endotoxin failures often trace back to water systems or component handling, not the sterilization step itself.

    Examples

    • A manufacturer of sterile, implantable catheters performs LAL testing on each lot to ensure endotoxin levels meet USP <85> criteria before release.
    • During a facility audit, an FDA investigator reviews a device manufacturer's water system monitoring records, specifically checking for trends in endotoxin levels.
    • A company developing a new injectable drug delivery device validates its LAL test method to account for potential interference from the device's material composition.
    Common pitfalls
    • •Assuming sterilization eliminates endotoxins, which are heat-stable and require specific depyrogenation processes.
    • •Failing to routinely monitor water systems for endotoxin levels, a common source of contamination.
    • •Not validating the LAL test method for each specific device or material, which can lead to inhibition or enhancement.
    • •Using an LAL test method not suitable for the product's matrix, yielding inaccurate results.
    • •Overlooking the endotoxin limits specified in relevant pharmacopeias or standards for the device type.

    Frequently asked questions

    Endotoxins are potent pyrogens that can cause fever, inflammation, and shock in patients. Testing ensures patient safety by confirming that endotoxin levels in medical devices are below harmful thresholds.

    Related terms

    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Latest in MedTech

    Sources

    3 sources

    Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Tier 1Binding law and standards· 1Tier 2Regulator guidance and consensus· 2
    Link health: 3 verified· last checked 2026-06-20
    USP·1IMDRF/GHTF·1FDA·1
    1. 1
      USP <85>
      Tier 1 Verified
      USPusp.org
    2. 2
      GHTF/IMDRF Process Validation Guidance
      Tier 2 Verified
      IMDRF/GHTFimdrf.org
    3. 3
      FDA - Device Manufacturing
      Tier 2 Verified
      FDAfda.gov

    Inline markers like [1] jump to the matching reference above.